Modern Action logo
IssuesBillsBriefingNewsletterAbout
Donate
Donate
Modern Action

Navigation

Menu

01HomeFront page→02IssuesActive issue pages→03BillsLegislation index→04BriefingDaily context→05NewsletterWeekly Watchlist→06AboutMission and team→07DonateSupport the work→

Account

Sign In→Get Started→
Modern Action

Find the bills behind the news, understand what Congress can do, and contact your representatives with a specific message.

Platform

  • Contact Congress
  • Write to Congress
  • Browse Bills
  • Track Bills

Resources

  • Find My Representatives
  • Contact My Representatives
  • How to Contact Representatives
  • Does Contacting Congress Work?
  • Newsletter

Support

  • About
  • Contact Us
  • Press
  • Accessibility

Legal

  • Privacy Policy
  • Terms of Service
  • Cookie Policy
  • Accessibility

Stay informed about legislation

Get weekly updates on important bills and how to take action.

© 2026 Modern Action. All rights reserved.

Made with ❤️ for democracy
All systems operational

Contact Congress about H.R. 4317: PBM Reform Act of 2025

This bill would add new rules for PBMs, the companies that manage drug benefits. It would protect pharmacy access in Medicare, require more price and rebate reporting, and ban spread pricing in Medicaid. Many of the biggest changes would start in 2028 or later, not right away.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

PBM Reform Act of 2025 is a House bill in committee. The latest recorded action: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Latest action on H.R. 4317: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Who this affects: This bill mainly affects people who get prescription drugs through Medicare, Medicaid, or job-based health coverage, along with the companies and pharmacies that handle those benefits. Medicare patients and local pharmacies could feel the pharmacy network changes most directly. PBMs, health plans, insurers, employers, and state Medicaid programs would face the biggest new reporting, payment, and compliance duties.

Why this matters: This bill matters because PBMs help control drug prices, pharmacy access, and where health plan money goes, but much of that system is hard for the public to see. The bill tries to make those payment flows more visible and stop some pricing practices lawmakers think raise costs or hurt local pharmacies. If the rules work as intended, they could improve oversight and protect access to nearby pharmacies. But the real effects on premiums, out-of-pocket costs, and covered drugs are still uncertain.

Key provisions in H.R. 4317

  • Medicare Part D plans would have to let in any pharmacy that agrees to the standard contract terms. HHS must define those "reasonable and relevant" terms by April 2028, and the rule starts being enforced in 2029.
  • Pharmacies would get a formal way to file complaints if a Medicare drug plan breaks the contract standards. HHS could investigate and use civil money penalties or other penalties if it finds a violation.
  • The bill creates a new category called "essential retail pharmacies" based on distance rules and whether an area lacks enough pharmacy access. HHS must publish reports at least every two years through 2034 comparing payments, network access, and patient out-of-pocket costs at those pharmacies and other pharmacies.
  • PBMs in Medicare Part D could keep only flat service fees that match fair market value for real services. They would have to pass all drug maker rebates and discounts through to the health plan, and plans and HHS could audit them and require detailed yearly data.
  • PBMs would have to cover penalties tied to jobs that Medicare plans handed over to them. If a PBM has to return improper payments, the plan sponsor must pass that money on to the federal government.

How Modern Action helps you take action on H.R. 4317

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 4317

What is H.R. 4317?
This bill would add new rules for PBMs, the companies that manage drug benefits. It would protect pharmacy access in Medicare, require more price and rebate reporting, and ban spread pricing in Medicaid. Many of the biggest changes would start in 2028 or later, not right away.
How do I support or oppose H.R. 4317?
Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.
Who should I contact about H.R. 4317?
Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.
Can Modern Action explain H.R. 4317 before I act?
Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.

Keep acting on Modern Action

More ways to act on this issue

Compare the broader issue and related bills without leaving Modern Action.

Related bills

  • Take action on H.R. 1768: Lower Costs for Everyday Americans Act
  • Take action on S. 891: Bipartisan Health Care Act
  • Take action on S. 3345: PBM Price Transparency and Accountability Act
  • Take action on H.R. 7148: Consolidated Appropriations Act, 2026